| lacosamide / Generic mfg. |
NCT00238524: A Trial to Assess the Efficacy and Safety of SPM 927 (Lacosamide) in Subjects With Painful Distal Diabetic Neuropathy |
|
|
| Completed | 3 | 357 | Europe | SPM 927 | UCB Pharma | Diabetic Neuropathy | 01/05 | 01/05 | | |
NCT00135109: Trial to Assess the Efficacy and Safety of SPM 927 (200, 400, and 600mg/Day) in Subjects With Painful Distal Diabetic Neuropathy |
|
|
| Completed | 3 | 654 | US | SPM 927 | UCB Pharma | Diabetic Neuropathies | 12/05 | 12/05 | | |
NCT00220415 / 2004-000290-58: A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Trial to Investigate the Efficacy and Safety of SPM 927 (200mg/Day and 400mg/Day) as Adjunctive Therapy in Subjects With Partial Seizures With or Without Secondary Generalization |
|
|
| Completed | 3 | | Europe | SPM 927 | UCB Pharma | Partial Seizures With or Without Secondary Generalization | 01/06 | 01/06 | | |
NCT00136019: SPM 927 (400mg/Day and 600mg/Day) as Adjunctive Therapy in Subjects With Partial Seizures With or Without Secondary Generalization |
|
|
| Completed | 3 | 400 | US | SPM 927 | UCB Pharma | Epilepsy | 08/06 | 08/06 | | |
| Completed | 3 | 551 | Europe | SPM 929, Lacosamide, Placebo | UCB Pharma, SCHWARZ BIOSCIENCES GmbH - Part of UCB Group | Painful Diabetic Neuropathy | 06/07 | 06/07 | | |
| Completed | 3 | 371 | Europe | Lacosamide, SPM 927 | UCB Pharma, SCHWARZ BIOSCIENCES GmbH - Part of UCB Group | Painful Diabetic Neuropathy | 10/07 | 10/07 | | |
NCT00655551 / 2014-004378-40: Safety of Intravenous Lacosamide Dose Followed by Twice Daily Oral Lacosamide in Subjects With Partial-onset Seizures |
|
|
| Completed | 3 | 100 | US | lacosamide, Vimpat | UCB BIOSCIENCES, Inc. | Partial Epilepsies, Partial Onset Seizures | 09/09 | 09/09 | | |
| Completed | 3 | 308 | US | lacosamide | UCB BIOSCIENCES, Inc. | Partial Epilepsies | 10/09 | 10/09 | | |
| Completed | 3 | 97 | US | lacosamide, Vimpat | UCB BIOSCIENCES, Inc. | Partial Epilepsies, Partial Onset Seizures | 06/10 | 06/10 | | |
| Completed | 3 | 376 | Europe, RoW | Lacosamide, SPM 927, LCM | UCB Pharma | Epilepsy | 08/10 | 08/10 | | |
| Completed | 3 | 621 | Europe, RoW | Lacosamide, Vimpat | UCB Pharma | Painful Diabetic Neuropathy | 01/11 | 01/11 | | |
| Completed | 3 | 426 | Canada, US, Europe, RoW | Lacosamide, Vimpat | UCB BIOSCIENCES, Inc. | Epilepsy | 12/12 | 12/12 | | |
| Terminated | 3 | 11 | Europe | Lacosamide, Vimpat, Levetiracetam, Keppra | UCB Pharma | Epilepsy, Partial | 03/13 | 03/13 | | |
| Completed | 3 | 120 | US, Europe, RoW | Lacosamide, VIMPAT®, SPM927, Harkoseride | UCB Pharma | Epilepsy | 12/13 | 12/13 | | |
NCT01710657 / 2014-003622-41: A Trial to Evaluate the Efficacy and Safety of Adjunctive Therapy With Lacosamide in Adults With Partial-Onset Seizures |
|
|
| Completed | 3 | 548 | Japan, RoW | Lacosamide 50 mg, Vimpat, Lacosamide 100 mg, Placebo | UCB Pharma SA, UCB Japan Co. Ltd. | Epilepsy, Partial Onset Seizures | 07/14 | 08/14 | | |
NCT02192814: Open-label Study to Evaluate the Safety and Tolerability of iv Lacosamide in Japanese Adults With Partial-onset Seizures |
|
|
| Completed | 3 | 9 | Japan | Lacosamide (200 mg/20 mL), Vimpat | UCB Japan Co. Ltd., Parexel | Epilepsy, Partial-onset Seizures | 10/14 | 12/14 | | |
NCT00530855 / 2007-005440-25: Trial to Assess Long-term Lacosamide (LCM) Monotherapy Use and Safety of LCM Monotherapy and Adjunctive Therapy for Partial-onset Seizures |
|
|
| Completed | 3 | 322 | Canada, US, Europe, RoW | Lacosamide, Vimpat | UCB Pharma | Epilepsy | 12/14 | 12/14 | | |
SP0993, NCT01243177 / 2010-019765-28: Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older |
|
|
| Completed | 3 | 888 | Europe, Canada, Japan, US, RoW | Lacosamide, Vimpat®, Carbamazepine-Controlled Release, Tegretol® Retard Tablets 200 mg | UCB BIOSCIENCES GmbH, Eden Sarl | Epilepsy, Monotherapy | 07/15 | 08/15 | | |
NCT01465997 / 2010-021238-74: Evaluating Long Term Safety of Lacosamide (LCM) to Carbamazepine Controlled-release (CBZ-CR); Initial Monotherapy in Epilepsy Subjects 16 Years and Older |
|
|
| Completed | 3 | 551 | Canada, Japan, US, Europe, RoW | Lacosamide, VIMPAT film-coated tablets, Carbamazepine-Controlled Release (CBZ-CR), Tegretol® Retard Tablets 200 mg | UCB BIOSCIENCES GmbH, Eden Sarl | Epilepsy, Monotherapy | 01/17 | 01/17 | | |
NCT01921205 / 2012-004996-38: Study to Investigate Lacosamide as Add-on Therapy in Subjects ≥4 Years to <17 Years of Age With Partial Onset Seizures |
|
|
| Completed | 3 | 404 | US, Europe, RoW | Lacosamide, Vimpat(R), Placebo | UCB Pharma | Epilepsy | 01/17 | 01/17 | | |
NCT02124564: A Trial to Evaluate the Long Term Safety and Tolerability of Lacosamide Taken as Monotherapy in Adults With Partial-onset Seizures |
|
|
| Completed | 3 | 19 | Japan | Lacosamide, Vimpat | UCB Japan Co. Ltd. | Epilepsy, Partial-onset Seizures | 11/17 | 11/17 | | |
VALOR, NCT02408523 / 2011-003100-21: A Study to Assess the Safety and Efficacy of Lacosamide Versus Placebo (a Pill Without Active Medication) in Patients With Idiopathic Generalised Epilepsy Who Are Already Taking Anti-epileptic Medications |
|
|
| Completed | 3 | 242 | Europe, Japan, US, RoW | Lacosamide Tablet, Vimpat, Lasosamide Oral Solution, Placebo Tablet, Placebo Oral Solution | UCB BIOSCIENCES, Inc., Pharmaceutical Research Associates | Epilepsy | 04/19 | 06/19 | | |
NCT01832038 / 2019-004756-11: Study to Evaluate the Safety, Tolerability, and Efficacy of Long-term Adjunctive Therapy With Lacosamide in Adults With Partial-onset Seizures |
|
|
| Completed | 3 | 473 | Japan, RoW | Lacosamide, Vimpat | UCB Pharma SA, UCB Japan Co. Ltd. | Epilepsy, Partial-onset Seizures | 07/19 | 07/19 | | |
NCT02582866 / 2015-001549-96: A Clinical Study to Investigate the Long-term Use of Lacosamide as Monotherapy in Subjects Who Completed Study SP0994 |
|
|
| Completed | 3 | 106 | Europe, Japan, RoW | Lacosamide, Vimpat, SPM927, LCM | UCB Biopharma S.P.R.L., Parexel | Epilepsy | 01/20 | 01/20 | | |
NCT02477839 / 2013-000717-20: Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects ≥1 Month to <4 Years With Partial-onset Seizures |
|
|
| Completed | 3 | 255 | Europe, US, RoW | Lacosamide, Vimpat, UCB Code: SPM 927, Abbreviated name: LCM, Placebo, PBO | UCB BIOSCIENCES, Inc. | Epilepsy With Partial-onset Seizures | 05/20 | 05/20 | | |
NCT01964560 / 2012-005012-26: A Clinical Study to Investigate the Efficacy and Safety of Lacosamide as an Add on Therapy in Children With Epilepsy With Partial-onset Seizures |
|
|
| Completed | 3 | 540 | Europe, US, RoW | Lacosamide, VIMPAT | UCB BIOSCIENCES, Inc., UCB Biopharma SRL | Epilepsy | 04/22 | 04/22 | | |
| Completed | 3 | 239 | Europe, Japan, US, RoW | Lacosamide Tablet, Vimpat, LCM, Lacosamide Oral Solution | UCB BIOSCIENCES, Inc. | Epilepsy | 03/23 | 03/23 | | |
NCT04627285 / 2020-001478-30: A Study to Test the Long-term Use of Oral Lacosamide in Pediatric Study Participants Who Completed NCT01964560 (EP0034) or NCT00938912 (SP848) and Received Lacosamide Treatment |
|
|
| Active, not recruiting | 3 | 48 | Europe, RoW | Lacosamide | UCB Biopharma SRL | Epilepsy | 07/25 | 07/25 | | |
NCT00235469: A Trial to Assess the Efficacy and Safety of SPM 927 in Subjects With Painful Distal Diabetic Neuropathy |
|
|
| Completed | 2/3 | 496 | US | SPM 927 | UCB Pharma | Diabetic Neuropathy | 06/05 | 06/05 | | |
| Completed | 2/3 | 160 | US | SPM 927 | UCB Pharma | Epilepsies, Partial | 05/06 | 05/06 | | |
NCT00235443: A Follow-On Trial to Assess the Long Term Safety and Efficacy of SPM 927 in Painful Distal Diabetic Neuropathy |
|
|
| Completed | 2/3 | 451 | US | lacosamide, SPM927 | UCB Pharma | Diabetic Neuropathy | 07/08 | 07/08 | | |
| Completed | 2/3 | 103 | Europe, US, RoW | Lacosamide, Vimpat | UCB BIOSCIENCES, Inc. | Epilepsy | 06/19 | 06/19 | | |
